Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy National Research Corporation stock | $43.32

Learn how to easily invest in National Research Corporation stock.

National Research Corporation is a diagnostics & research business based in the US. National Research Corporation shares (NRC) are listed on the NASDAQ and all prices are listed in US Dollars. National Research Corporation employs 485 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in National Research Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NRC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

National Research Corporation stock price (NASDAQ: NRC)

Use our graph to track the performance of NRC stocks over time.

National Research Corporation shares at a glance

Information last updated 2021-10-23.
Latest market close$43.32
52-week range$41.19 - $58.74
50-day moving average $45.29
200-day moving average $48.31
Wall St. target priceN/A
PE ratio 30.9429
Dividend yield $0.24 (0.55%)
Earnings per share (TTM) $1.40

Buy National Research Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy National Research Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

National Research Corporation price performance over time

Historical closes compared with the close of $43.32 from 2021-10-22

1 week (2021-10-15) 1.03%
1 month (2021-09-24) -4.07%
3 months (2021-07-23) -17.09%
6 months (2021-04-23) -10.70%
1 year (2020-10-23) -19.25%
2 years (2019-10-24) -22.93%
3 years (2018-10-24) 19.67%
5 years (2016-10-24) 170.75%

Is National Research Corporation under- or over-valued?

Valuing National Research Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of National Research Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

National Research Corporation's P/E ratio

National Research Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, National Research Corporation shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

National Research Corporation's EBITDA

National Research Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $54.4 million.

The EBITDA is a measure of a National Research Corporation's overall financial performance and is widely used to measure a its profitability.

National Research Corporation financials

Revenue TTM $140.1 million
Operating margin TTM 33.62%
Gross profit TTM $84.1 million
Return on assets TTM 21.92%
Return on equity TTM 58.99%
Profit margin 25.66%
Book value $3.00
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting National Research Corporation shares

There are currently 296,276 National Research Corporation shares held short by investors – that's known as National Research Corporation's "short interest". This figure is 8.2% down from 322,839 last month.

There are a few different ways that this level of interest in shorting National Research Corporation shares can be evaluated.

National Research Corporation's "short interest ratio" (SIR)

National Research Corporation's "short interest ratio" (SIR) is the quantity of National Research Corporation shares currently shorted divided by the average quantity of National Research Corporation shares traded daily (recently around 24813.735343384). National Research Corporation's SIR currently stands at 11.94. In other words for every 100,000 National Research Corporation shares traded daily on the market, roughly 11940 shares are currently held short.

However National Research Corporation's short interest can also be evaluated against the total number of National Research Corporation shares, or, against the total number of tradable National Research Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case National Research Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 National Research Corporation shares in existence, roughly 10 shares are currently held short) or 0.028% of the tradable shares (for every 100,000 tradable National Research Corporation shares, roughly 28 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against National Research Corporation.

Find out more about how you can short National Research Corporation stock.

National Research Corporation share dividends

26%

Dividend payout ratio: 26.12% of net profits

Recently National Research Corporation has paid out, on average, around 26.12% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.11% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), National Research Corporation shareholders could enjoy a 1.11% return on their shares, in the form of dividend payments. In National Research Corporation's case, that would currently equate to about $0.24 per share.

While National Research Corporation's payout ratio might seem fairly standard, it's worth remembering that National Research Corporation may be investing much of the rest of its net profits in future growth.

National Research Corporation's most recent dividend payout was on 14 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 28 September 2021 (the "ex-dividend date").

National Research Corporation share price volatility

Over the last 12 months, National Research Corporation's shares have ranged in value from as little as $41.185 up to $58.7364. A popular way to gauge a stock's volatility is its "beta".

NRC.US volatility(beta: 0.75)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while National Research Corporation's is 0.7529. This would suggest that National Research Corporation's shares are less volatile than average (for this exchange).

National Research Corporation overview

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations.

Frequently asked questions

What percentage of National Research Corporation is owned by insiders or institutions?
Currently 45.536% of National Research Corporation shares are held by insiders and 44.296% by institutions.
How many people work for National Research Corporation?
Latest data suggests 485 work at National Research Corporation.
When does the fiscal year end for National Research Corporation?
National Research Corporation's fiscal year ends in December.
Where is National Research Corporation based?
National Research Corporation's address is: 1245 Q Street, Lincoln, NE, United States, 68508
What is National Research Corporation's ISIN number?
National Research Corporation's international securities identification number is: US6373722023
What is National Research Corporation's CUSIP number?
National Research Corporation's Committee on Uniform Securities Identification Procedures number is: 637372103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site